ERBB2 and breast carcinoma: In breast cancer, Ki‐67 expression is utilized to distinguish between luminal A and luminal B subtypes, assess the efficacy of abemaciclib in high‐risk ER‐positive/HER2‐negative breast cancer, and predict systemic chemotherapy responses in neoadjuvant therapy [22].